A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma
Cancer - Mycosis Fungoides,
Cancer - Non-Hodgkin's Lymphoma
Lauren C Pinter-Brown
For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email firstname.lastname@example.org.